These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9583927)

  • 1. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.
    Jha TK; Olliaro P; Thakur CP; Kanyok TP; Singhania BL; Singh IJ; Singh NK; Akhoury S; Jha S
    BMJ; 1998 Apr; 316(7139):1200-5. PubMed ID: 9583927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial.
    Thakur CP; Bhowmick S; Dolfi L; Olliaro P
    Trans R Soc Trop Med Hyg; 1995; 89(2):219-23. PubMed ID: 7778155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.
    Thakur CP; Olliaro P; Gothoskar S; Bhowmick S; Choudhury BK; Prasad S; Kumar M; Verma BB
    Trans R Soc Trop Med Hyg; 1992; 86(6):615-6. PubMed ID: 1337634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.
    Chunge CN; Owate J; Pamba HO; Donno L
    Trans R Soc Trop Med Hyg; 1990; 84(2):221-5. PubMed ID: 2167522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.
    Thakur CP; Kanyok TP; Pandey AK; Sinha GP; Zaniewski AE; Houlihan HH; Olliaro P
    Trans R Soc Trop Med Hyg; 2000; 94(4):429-31. PubMed ID: 11127250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis.
    Hepburn NC; Tidman MJ; Hunter JA
    Trans R Soc Trop Med Hyg; 1994; 88(6):700-3. PubMed ID: 7886779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone.
    Seaman J; Pryce D; Sondorp HE; Moody A; Bryceson AD; Davidson RN
    J Infect Dis; 1993 Sep; 168(3):715-20. PubMed ID: 8394861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.
    Thakur CP; Sinha GP; Pandey AK; Kumar N; Kumar P; Hassan SM; Narain S; Roy RK
    Ann Trop Med Parasitol; 1998 Jul; 92(5):561-9. PubMed ID: 9797829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study.
    Thakur CP; Kumar M; Kumar P; Mishra BN; Pandey AK
    Br Med J (Clin Res Ed); 1988 Jun; 296(6636):1557-61. PubMed ID: 2840172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis.
    Poli A; Sozzi S; Guidi G; Bandinelli P; Mancianti F
    Vet Parasitol; 1997 Aug; 71(4):263-71. PubMed ID: 9299695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
    Tamiru A; Mohammed R; Atnafu S; Medhin G; Hailu A
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009713. PubMed ID: 34464401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
    Musa A; Khalil E; Hailu A; Olobo J; Balasegaram M; Omollo R; Edwards T; Rashid J; Mbui J; Musa B; Abuzaid AA; Ahmed O; Fadlalla A; El-Hassan A; Mueller M; Mucee G; Njoroge S; Manduku V; Mutuma G; Apadet L; Lodenyo H; Mutea D; Kirigi G; Yifru S; Mengistu G; Hurissa Z; Hailu W; Weldegebreal T; Tafes H; Mekonnen Y; Makonnen E; Ndegwa S; Sagaki P; Kimutai R; Kesusu J; Owiti R; Ellis S; Wasunna M
    PLoS Negl Trop Dis; 2012; 6(6):e1674. PubMed ID: 22724029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica.
    Teklemariam S; Hiwot AG; Frommel D; Miko TL; Ganlov G; Bryceson A
    Trans R Soc Trop Med Hyg; 1994; 88(3):334-9. PubMed ID: 7974682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
    N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar.
    Mishra M; Biswas UK; Jha AM; Khan AB
    Lancet; 1994 Dec; 344(8937):1599-600. PubMed ID: 7983993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
    Miret JA; Moreno J; Nieto J; Carter KC; Mullen AB; Ambros L; Rodríguez C; San Andrés MI; González F
    Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with amphotericin B in sodium stibogluconate--unresponsive cases of visceral Leishmaniasis in north Bihar.
    Giri OP; Singh AN
    J Assoc Physicians India; 1994 Sep; 42(9):690-1. PubMed ID: 7883660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.